# Optimization of Treatment Strategy for Unresectable cN3 Esophageal Squamous Cell Carcinoma

> **NCT06122493** · PHASE2 · RECRUITING · sponsor: **Ruijin Hospital** · enrollment: 48 (estimated)

## Conditions studied

- Esophageal Squamous Cell Carcinoma

## Interventions

- **DRUG:** Tirelizumab
- **DRUG:** Nab paclitaxel
- **DRUG:** Carboplatin
- **RADIATION:** Radiotherapy

## Key facts

- **NCT ID:** NCT06122493
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-11-01
- **Primary completion:** 2026-11-01
- **Final completion:** 2026-11-01
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2023-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06122493

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06122493, "Optimization of Treatment Strategy for Unresectable cN3 Esophageal Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT06122493. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*